GreenTree Medical Writing, LLC
University of Wisconsin-River Falls, River Falls, WI
M.S. (organic chemistry) University of Maryland-College Park, College Park, MD
Medical Writing Skills
• Experienced with writing pharmaceutical regulatory documents (eg, clinical study reports, investigator
brochures, safety and efficacy summaries for NDA and CTD filings, clinical overviews, IND annual reports, 4-month safety updates, and regulatory deficiency responses).
• Experienced in preparing/submitting manuscripts, abstracts, posters, and slide sets for oral
• Experienced with ICH E3, ICH M4, GCP, AMA style, MS Office, Documentum, Coredossier.
• American Medical Writer’s Association (AMWA) core curriculum certificate in Pharmaceutical
• Six-sigma trained/ Green Belt certified. • Comfortable working with international clients and under the strict regulations required by the
• Strong team leader and independent writer
Owner, GreenTree Medical Writing, LLC
• I have produced many CSRs in therapeutic areas including oncology (including skin cancers),
cardiovascular, neuromodulation, pain, inflammation, metabolic disorders, malaria, spinal fusion, and fertility. I have also prepared manuscripts, literature reviews, and regulatory safety documents for devices including those for spinal surgery applications, intrathecal drug delivery, and deep brain stimulation. Other extensive project experience has included a mix of manuscripts, posters, and white papers for clinical reporting.
Senior Medical Writer (3M Pharmaceuticals).
• Worked with cross-functional and global teams to prepare documents for the FDA and
international regulatory agencies such as EMEA and the TGA (clinical study reports, clinical sections of annual reports, NDA clinical safety and efficacy summaries, CTD safety and efficacy summaries, and deficiency responses);
• Worked with internal and external authors to prepare and submit abstracts and posters for
• Was the lead writer for 3M’s Basal Cell Carcinoma program -required to track writer progress on
various projects, keep writer’s informed of program direction and decisions made by the clinical research project team (CRPT) , to update the CRPT with information relating to publications/strategy and writer timeline and resource issues
• Led 3M’s clinical publication planning team which consisted of writers, clinical team members,
and marketing. This team proactively planned and tracked the publication timing and strategy for 2 primary programs as well as several smaller ones with less mature clinical programs.
• Worked extensively with 3M colleagues around the world using communication tools such as
• Led a six-sigma greenbelt team to optimize our process for preparing the clinical sections of
annual reports. Included drafting the new SOP and training the clinical group on the SOP.
• Led 3M Pharmaceuticals’ process for posting clinical study results to clinicalstudyresults.org.
Jun 2000-May 2003
Advanced Medical Writer (3M Pharmaceuticals/Medical Operations Department).
Mar 1997-Jun 2000
Advanced Research Chemist (3M Pharmaceuticals/Drug Discovery).
Dec 1993-Jan 1997
Assistant Scientist (Pfizer/ New Leads Drug Discovery Department).
Masters thesis research toward the synthesis of macrocyclic lactones through carbon-carbon bond formation using TMS-Mn(CO)5.
Sep 1991-May 1993
Graduate school teaching assistant for general chemistry and organic chemistry university students at the University of Maryland.
• “Ethics and the Medical Writing Freelancer”
Leslie Charles. Orally presented at the North Central
AMWA Chapter Fall Event Panel Discussion; University of St. Thomas, St. Paul, MN, September 24, 2008
• “It’s Not Just for Manufacturing Anymore: Six Sigma Applications for Medical Writing”
Charles, Rhonda Dick, Anne Roush. Poster at AMWA 2004 Annual Conference
• “New Selective IRM’s
” Leslie Charles, Phil Heppner; Poster at 3M 1999 Pharmaceutical Annual Lab
• “Combinatorial Chemistry Comes to Life in Drug Discovery
” Leslie Charles, Steve Crooks, Phil
Heppner; Poster at 3M life Sciences Tech forum event
• “Combinatorial Chemistry: 5-LO and PDE-IV Projects
” Steve Crooks, Leslie Charles, Phil
Heppner, Peter Maye, Poster at 3M 1997 Pharmaceutical Annual Lab Review
• “The High Speed Pursuit of EGFR-Inhibitors
” Leslie Meerdink (Charles), Beth Cooper, Lee
Arnold, Cathy Diorio, Jim Moyer, Jim Hauske. Poster at Pfizer Drug Discovery technical event.
• Charles L, Reidenbach F. Publication planners and medical writers: a natural alliance. AMWA Journal
• Charles LJ. AMWA Annual Meeting Open Session Review: How to Evaluate a Medical Writing
Contract. AMWA Journal
• Crooks SL, Charles LJ. Overview of Combinatorial Chemistry. Current Protocols in Pharmacology
• Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream in the treatment of superficial basal cell
carcinoma: results from two phase III randomized, vehicle-controlled studies. J Am Acad Dermatol
• Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, Ding L, Thissen MRT. Imiquimod
5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol
• Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, Andres K, Amies M, Owens
M. Efficacy of Topical Imiquimod Cream for the Treatment of Nodular Basal Cell Carcinoma: Comparison of Dosing Regimens. Arch Dermatol
• Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, Munzel U. Recurrence rate of
superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol
• Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in
assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril
• Foley P, Merlin K, Cumming S, Campbell J, Crouch R, Harrison S, Cahill J. A comparison of
cryotherapy and imiquimod for treatment of actinic keratosis: lesion clearance, safety, and skin quality outcomes. J Drugs Dermatol
Heterocyclic Ether Substituted Imidazoquinolines. Issued Dec. 16, 2003
Aryl Ether Substituted Imidazoquinolines. Issued Dec. 30, 2003
Aryl Ether Substituted Imidazoquinolines. Issued Jan 13, 2004
Aryl Ether Substituted Imidazoquinolines. Issued Jan 24, 2006
Scholarships and Awards
• 3M Pharmaceuticals IRM award-2005
• 3M Technical Circle of Excellence Award nominee-2003
• 3M Pharmaceuticals Recognition Award for Contributions to the Scientific Literature-2001
• 3M Language Society Student of the Year-2000
• 3M Research Scholarship-1990
• U.F.E. Inc. Scholarship-1989 Committees and Professional Organizations
• Editorial Board Member-AMWA Journal (2010) • Council of Science Editors (member 2009-2010) • The International Publication Planning Association (member since 2009) • American Medical Writers Association (member since 2000)
• American Medical Writers Association (AMWA) North Central Chapter Co-treasurer (2007) • 3M IRM Award Selection Committee Officer (2006) • AMWA North Central Chapter Treasurer (2005-2007) • AMWA North Central Chapter Secretary (2001-2005) • Technical Circle of Excellence Selection Committee (3M Pharmaceuticals, 1999)
The Catamaran™ Preferred Drug List (PDL) is a guide identifying preferred medicines within select therapeutic categories. The PDL is an abbreviated drug list which includes the most commonly prescribed Tier 1 and Tier 2 medicines. Tier 1 drugs are listed in lowercase italics and Tier 2 drugs are listed in CAPS. This listing is revised periodical y as new drugs and new prescribing infor
Seattle-King County Emergency Medical Services Division Public Health - Seattle/King County 401 5th Avenue, Suite 1200 Seattle, WA 98104 (206) 296-4863 CBT/OTEP 385 – Environmental Emergencies Introduction Heat and cold illnesses are triggered when the body is unable to maintain a constant temperature. A fundamental knowledge of heat mechanisms and factors that affect the body’s ability t